Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Outlook Therapeutics Inc (OTLKW)

Outlook Therapeutics Inc (OTLKW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference GlobeNewswire - Wed Nov 6, 7:05AM CST

OTLK : 5.13 (-2.84%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment GlobeNewswire - Thu Oct 17, 8:00AM CDT

OTLK : 5.13 (-2.84%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term Milestones Globe Newswire - Wed Aug 10, 2022

Planned re-submission of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) on track ...

OTLKW : 0.03 (-1.96%)
OTLK : 5.13 (-2.84%)
Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference Globe Newswire - Thu Aug 4, 2022

ISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 5.13 (-2.84%)
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note Globe Newswire - Tue Jul 5, 2022

ISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 5.13 (-2.84%)
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010 Globe Newswire - Tue Jun 14, 2022

Outlook Therapeutics reiterates expected re-submission of BLA by September 2022 following receipt of additional correspondence from U.S. Food and Drug...

OTLKW : 0.03 (-1.96%)
OTLK : 5.13 (-2.84%)
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD Globe Newswire - Tue May 31, 2022

ISELIN, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 5.13 (-2.84%)
Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference Globe Newswire - Wed May 18, 2022

ISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 5.13 (-2.84%)
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update Globe Newswire - Fri May 13, 2022

ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) submitted to U.S. Food and Drug Administration (FDA); PDUFA date expected to be...

OTLKW : 0.03 (-1.96%)
OTLK : 5.13 (-2.84%)
Outlook Therapeutics to Participate in Retina World Congress 2022 Globe Newswire - Tue May 10, 2022

ISELIN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop...

OTLKW : 0.03 (-1.96%)
OTLK : 5.13 (-2.84%)

Barchart Exclusives

1 AI Stock to Buy and Hold for Long-Term Growth Barchart - Thu Nov 21, 7:18PM CST
Pure Storage stands out in AI data storage, bolstered by a new partnership with CoreWeave and a solid financial track record, making it an intriguing stock for AI-focused investors Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot